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doi:10.1016/j.kjms.2011.10.012Abstract Good’s syndrome, also known as thymoma with combined immunodeficiency, is
rare. The immunodeficiency may precede, arise concurrently with or follow the diagnosis of
thymoma. In addition to myasthenia gravis and Good’s syndrome, paraneoplastic syndromes
associated with thymoma can also be manifested with hematological disorders, such as pure
red cell aplasia, aplastic anemia, agranulocytosis, hemolytic anemia, pernicious anemia,
and paroxysmal nocturnal hemoglobinuria. Myelodysplastic syndrome is a group of clonal
hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more line-
ages, ineffective hematopoiesis, and potential precursors of acute leukemia. One proposed
pathogenesis of myelodysplasia is autoantibodies that directly reject against hematopoietic
cells, but this situation is rare in thymoma. Herein, we report a thymoma patient with unique
paraneoplastic syndromes who developed myelodysplasia prior to Good’s syndrome. Early and
accurate diagnosis of myelodysplastic syndrome is important for disease management, espe-
cially in patients whose myelodysplastic syndrome is possibly derived from autoimmunity.
For thymoma patients with recurrent infections, comprehensive immunologic studies to
exclude the possibility of Good’s syndrome and prophylactic intravenous immunoglobulin
infusion in suitable candidates are warranted.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Hematology and Oncology, Department of Internal Medicine, Kaohsiung Veterans General Hospital,
3, Taiwan.
m.tw (L.-P. Chen).
vier Taiwan LLC. All rights reserved.
Figure 1. Chest X-ray showed a geographic pattern of soft
tissue mass at the left mediastinum. Chest computed tomog-
raphy demonstrated multiple bulky confluent lobulated lymph
nodes in the anterior mediastinum (inset).
Figure 2. Microscopically, two areas were sharply demar-
cated into upper left and lower right. Type AB thymoma was
supported by the lymphocyte-poor type A area which contained
neoplastic spindle epithelial cells and a more lymphocyte-rich
type B component (H&E, 40).
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Good’s syndrome (thymoma with combined immunodefi-
ciency) is rare and comprises less than 5% of thymoma
patients. The main immunological abnormalities include
hypogammaglobulinemia, few or absence of B lymphocytes,
inversion of the CD4/CD8 T cell ratio, low level of CD4 T
cells, and impaired T cell mitogenic response [1]. Due to
the dysfunction of both B and T lymphocytes, patients with
Good’s syndrome are more vulnerable to various pathogens,
such as encapsulated bacteria, virus, fungus, and oppor-
tunistic infections. In addition to myasthenia gravis and
Good’s syndrome, paraneoplastic syndromes associated
with thymoma (parathymic syndromes) could also present
with autoimmune-mediated hematological disorders, such
as pure red cell aplasia, aplastic anemia, agranulocytosis,
hemolytic anemia, pernicious anemia, and paroxysmal
nocturnal hemoglobinuria [1e6]. Furthermore, myelodys-
plastic syndrome (MDS) is a heterogeneous group of clonal
hematopoietic stem cell diseases characterized by cyto-
penia(s), dysplasia in one or more lineages, and ineffective
hematopoiesis, and is associated with a variable risk of
transformation to acute leukemia. For patients with MDS,
the infection episodes usually depend on the severity of
neutropenia. To our knowledge, only one case with Good’s
syndrome followed by myelodysplasia was reported in the
literature [7]. Herein, we report a thymoma patient who
manifested with repeated infections and unique paraneo-
plastic syndromes, and where the onset of myelodysplasia
was before the diagnosis of Good’s syndrome.
Case report
A 50-year-old woman initially presented with carbuncle in
the tragus of the right ear in November 2006. Her initial white
blood cell (WBC) count was 4.52 109/L with differential
counts as follows: segment, 28%, band, 7%, and lymphocyte,
51%. Her condition improved after receiving incision and
debridement plus antibiotics therapy. However, about 10
months later, in September 2007, she was hospitalized again
for urinary tract infection (UTI) with Escherichia coli (E. coli)
bacteremia. Her hemogram revealed a WBC count as
2.61 109/L with 17% Pelger-Huet-like cells in the peripheral
blood. The chest X-ray disclosed presence of a mediastinal
mass. Chest computed tomography (CT) scan further docu-
mented multiple confluent lobulated lymph nodes in the
anterior mediastinum (Fig. 1). Type AB thymoma was
confirmed by CT-guided biopsy and she received thymectomy
in October 2007 (Fig. 2). Acute E. coil pyelonephritis
occurred in November 2007. Moreover, chronic diarrhea,
pathology-proven multiple furuncles, and folliculitis of trunk
developed frequently after the operation.
In December 2008, she suffered from left gluteal cellulitis
with oxacillin-resistant Staphylococcus aureus (ORSA) iso-
lated. In addition, another episode of E. coli UTI occurred.
The laboratory data is summarized in Table 1. The abnormal
data included: WBC count, 3.53 109/L, hemoglobin,
9.3 g/dL, Pelger-Huet-like cell, 45% (Fig. 3A), immunoglob-
ulin (Ig) M, 15.9 mg/dL (reference range, 46e304 mg/dL),
CD4, 25% (reference range, 35e55%), CD3, 92% (reference
range, 65e85%), CD8, 61% (reference range, 20e36%), CD19,0% (reference range, 5e15%), and ratio of CD4/CD8, 0.44
(reference range, 1.5e2). Bone marrow aspiration revealed
normal cellularity (Fig. 3B) and increasing small-sized
mononuclear megakaryocytes (Fig. 3C and 3D). Microscopi-
cally, numerous defective neutrophils bore nuclei without
segmentation (Fig. 3E and 3F), and neither excess of blasts
nor ringed-sideroblasts were shown in the iron staining,
which was consistent with manifestations of MDS, the
subtype of refractory cytopenia with multilineage dysplasia.
In order to exclude the possibility of an incomplete resection
or recurrence of thymoma, a chest CT scan was performed
but it demonstrated no evidence of residual thymoma. The
Table 1 Summarized laboratory data of this patient.
Parameters Date Nov 2006 Sep 2007 Dec 2008 Reference range
White blood cell (109/L) 4.52 2.61 3.53 4e9.9
Hemoglobin (g/dL) 11.7 11.7 9.3 12.0e16.0
Platelet (109/L) 231 202 204 150e450
Pelger-Huet-like cell (%) 0 17 45 0
IgG (mg/dL) 752.0 751e1560
IgA (mg/dL) 166.0 82e453
IgM (mg/dL) 15.9 46e304
Lymphocyte subpopulations
CD3 (%) 92 65e85
CD4 (%) 25 35e55
CD8 (%) 61 20e36
CD19 (%) 0 5e15
CD4/CD8 0.44 1.5e2
Human immunodeficiency virus Negative Negative
Antinuclear antibodies Negative Negative
CDZ cluster of differentiation; IgZ immunoglobulin.
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confirmed the diagnosis of Good’s syndrome. She received
antibiotics therapy, incision, and debridement plus intrave-
nous immunoglobulin (IVIG) infusion for infection control.
She was lost to follow-up after the infection resolved.Discussion
Paraneoplastic syndromes of thymoma are presumed to
derive from autoimmunity. Except antibodies for the anti-
acetylcholine receptor in myasthenia gravis, the specific
antibodies for parathymic syndromes have yet to be iden-
tified. Paraneoplastic syndromes, such as immunodefi-
ciency and hematological disorders, may precede, arise
concurrently with or follow the diagnosis of thymoma. At
the same time, parathymic syndromes may or may not
respond to thymectomy.
There are some hypotheses of immunodeficiency in
Good’s syndrome. For example, the main function of the
fetal thymus is T-cell depletion of autoreactive clones and
the presence of thymoma breaks the balance of immuno-
surveillance; the compensation of immunodeficiency is pre-
sented by hyperplasia of the thymus; there are irrelative
events of immunodeficiency and thymoma, such as cytokines
released from bone marrow stromal cells, influencing both
thymic and B cell precursors [8]. Around 50% of Good’s
syndrome patients are characterized with B-lymphopenia
and 20% with panhypogammaglobulinemia. The level of
immunoglobulin is a good predictor of immunity but has
a poor sensitivity for infections [9]. Recurrent sinopulmonary
infection and chronic diarrhea are the most common mani-
festations in Good’s syndrome. Due to impaired humoral and
cellular immunity, Haemophilus influenzae, Streptococcus
pneumoniae, and infection with Pseudomonas species or
Klebsiella species are the most common infection situations
a Good’s syndrome patient could encounter. Opportunistic
viral infections of Cytomegalovirus and Herpes simplex virus
are also common [1]. Although no identical pathogen wasidentified in most cases with Good’s syndrome, the major
cause of chronic diarrhea is Giardia lamblia. For most
patients with Good’s syndrome, the hypogammaglobulin-
emia lasts or even worsens after the removal of the thymus.
In order to reduce the risk of various infections, the main-
tenance of adequate IgG by prophylactic IVIG is recom-
mended [1].
Concurrently, 12e16.2% of patients with MDS coexist
with autoimmune disorders [10]. One proposed pathogen-
esis in MDS is autoantibodies that directly reject against
hematopoietic cells, which was supported by the similar
immune dysregulation of CD4 and CD8 T cells found in
Good’s syndrome [11,12]. In addition, CD8 T cells are proved
to be involved in damaging hematopoietic precursors [6]. In
the National Comprehensive Cancer Network guidelines of
MDS, immunosuppressive treatments are reasonable choices
in patients with MDS and hypocellular bone marrow, HLA-
DR15, and positive clones of PNH or young individuals at
low- to intermediate-risk. Some thymoma patients with
cytopenia(s) improved after thymectomy and some were
responsive to adjuvant immunosuppressive agents (steroid,
cyclophosphamide, vincristine) or monoclonal antibody
(anti-CD52; Campath-1H) [13]. In the previously reported
72-year-old man with Good’s syndrome and myelodysplasia,
the myelodysplasia was diagnosed 8 years after thymec-
tomy. He became transfusion-independent after cyclo-
sporine therapy [7]. Furthermore, the survival of MDS
patients with immunological abnormalities was significantly
worse than those without immunological abnormalities, and
the outcomes of patients with an inverted CD4/CD8 ratio
were poorer than those with CD4/CD8 ratio >1 [14].
In our study case, the Pelger-Huet-like cells in peripheral
blood were found before the diagnosis of thymoma.
Although the diagnosis of MDS and Good’s syndrome was
confirmed 14 months after thymectomy, delayed diagnosis
was possible given because of the occurrence of similar
infections before and after the operation. Furthermore,
hypogammaglobulinemia was restricted to IgM despite of
undetectable peripheral pre-B or B cells. The presumed
Figure 3. Dysplasia showed in both myeloid series and megakaryocytes. (A) Normal nuclear segmentation of eosinophil versus
Pelger-Huet-like cell (arrow) with round nuclei, dense clumped coarse chromatin and normal cytoplasmic granules in the peripheral
blood (Wright’s stain, 1000). (B) Normal cellularity showed in bone marrow biopsy (H&E stain, 400). (C) Increased number of
small-sized megakaryocytes in the bone marrow aspiration (Wright’s stain, 100). (D) Mononucleated medium-sized megakaryo-
cyte (Wright’s stain, 1000). (E) Two Pelger-Huet-like cells in the bone marrow were pointed out by arrow (Wright’s stain, 1000).
(F) One Auer rod was found in the cytoplasm of a Pelger-Huet-like cell, shown by arrow (Wright’s stain, 1000).
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the coexisting monoclonal IgG or IgA [15]. Since she had
dysfunction of both innate (neutrophil granulocytes) and
adaptive immunity (B and T lymphocytes), she presented
with uncommon bacterial soft tissue and urinary tract
infection instead of sinopulmonary infection. At the same
time, unusual pathogens of E. coli and ORSA were isolated.
Moreover, cytopenias in MDS were defined as hemoglobin
<10 g/dL, absolute neutrophil count <1.8 109/L and
platelets <100 109/L by WHO classification. The diagnosis
of MDS can be made in patients with typical morphological
and/or cytogenetic abnormalities, but their hemograms are
normal. In this case, her platelet count was within normal
range during the whole course even though definite
mononucleated megakaryocytes showed in the bone
marrow. Since the incidence of thrombocytopenia corre-
lated with disease severity classified by the InternationalPrognostic Scoring System (IPSS) [16], an increased number
of dysmegakaryocytes to compensate ineffective mega-
karyopoiesis was presumed. Due to repeated infection,
reactive thrombocytosis might also play a role. However, it
was rather a pitfall for not performing a cytogenetic
examination for this patient, that we were unable to clas-
sify her risk level according to the IPSS. Immunosuppressive
treatment was considered reasonable for her due to her
high possibility of having autoimmunity-associated young
MDS. Although theoretically beneficial, there was no direct
evidence to support our treatment strategy since this
patient was lost to follow-up.
In conclusion, it is important to recognize the presence of
autoimmune-mediated myelodysplastic syndrome and adopt
immunosuppressive treatment as needed. For thymoma
patients with recurrent infections, Good’s syndrome must
be excluded by comprehensive immunologic investigations
240 L.-P. Chen et al.and prophylactic IVIG should be prescribed in suitable
candidates.
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